NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

From Moderna to Sellas: The Next Major Catalyst in Cancer Vaccines

Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.

From Moderna to Sellas: The Next Major Catalyst in Cancer Vaccines
Credit: Sellas Life Sciences
Already have an account? Sign in.
Featured/ 08/19/2026 · 11:49 AM
SLS
/ Don’t stop at just one post.

Related↓

SELLAS GPS Trial Nears Completion as Survival Times Extend Beyond Expectations
12/31/2025 · 11:12 AM

SELLAS GPS Trial Nears Completion as Survival Times Extend Beyond Expectations

SELLAS Life Sciences' Phase 3 REGAL trial for GPS in AML patients approaches 80-event threshold with 72 deaths reported, suggesting potential survival benefits as stock surges 100% in December.

/ Subscriber only
/ Read more

Feed↓

Expedia Stock Jumps to New 52-Week High as Analysts Raise Price Targets
08/24/2026 · 2:38 PM

Expedia Stock Jumps to New 52-Week High as Analysts Raise Price Targets

Evercore lifts Expedia’s PT to $430 (from $375); Wedbush raises its target to $417 (from $334) following the Q2 earnings beat and raised guidance.

/ Subscriber only
Alvotech: BofA Initiates Buy Rating as Biosimilar Launch Cycle Begins
Featured/ 08/24/2026 · 12:20 PM

Alvotech: BofA Initiates Buy Rating as Biosimilar Launch Cycle Begins

FDA clears Reykjavik plant as biosimilar launches drive commercial growth.

/ Subscriber only
Hims & Hers Placed in Visa Monitoring Program After Surge in Weight-Loss Chargebacks
08/24/2026 · 11:50 AM

Visa Flags Hims & Hers Over Excessive Disputes on $149 Weight-Loss Subscriptions

Visa flags Hims for high dispute rates on $39-to-$149 weight-loss memberships. Company faces fees, scrutiny, and must lower rate for 3 months.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe